[
  {
    "ts": null,
    "headline": "Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial",
    "summary": "Shares of the biotech  Kymera Therapeutics  are up 50% since Monday, when data from an early trial hinted that its pill might relieve dermatitis and asthma comparably to the  Regeneron Pharmaceuticals  blockbuster injectable Dupixent.  Shares of the Boston drug developer got several upgrades to a Buy.  Kymera’s Phase 1 study compared its pill to a placebo in 118 healthy volunteers.",
    "url": "https://finnhub.io/api/news?id=6b9a64a109eb77e5c86e2c0d8f42c5114fe906e97a9c8ae6fe1c38580560b155",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749154560,
      "headline": "Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial",
      "id": 135066040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of the biotech  Kymera Therapeutics  are up 50% since Monday, when data from an early trial hinted that its pill might relieve dermatitis and asthma comparably to the  Regeneron Pharmaceuticals  blockbuster injectable Dupixent.  Shares of the Boston drug developer got several upgrades to a Buy.  Kymera’s Phase 1 study compared its pill to a placebo in 118 healthy volunteers.",
      "url": "https://finnhub.io/api/news?id=6b9a64a109eb77e5c86e2c0d8f42c5114fe906e97a9c8ae6fe1c38580560b155"
    }
  },
  {
    "ts": null,
    "headline": "The New Twist In Regeneron's 23andMe Bankruptcy Buyout",
    "summary": "23andMe wants to reopen bidding on its assets after former CEO Anne Wojcicki put together a $305 million offer, topping Regeneron.",
    "url": "https://finnhub.io/api/news?id=b84e9291608dafba030917b343b234e5d563fdecc0b6c5b50003af69ad19e847",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749135058,
      "headline": "The New Twist In Regeneron's 23andMe Bankruptcy Buyout",
      "id": 135050452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "23andMe wants to reopen bidding on its assets after former CEO Anne Wojcicki put together a $305 million offer, topping Regeneron.",
      "url": "https://finnhub.io/api/news?id=b84e9291608dafba030917b343b234e5d563fdecc0b6c5b50003af69ad19e847"
    }
  },
  {
    "ts": null,
    "headline": "REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?",
    "summary": "REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.",
    "url": "https://finnhub.io/api/news?id=8ef4c847711b812db76cef7bb42143d35b90bf8308ea057dbb0a07d6878d43a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749127500,
      "headline": "REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?",
      "id": 135046541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.",
      "url": "https://finnhub.io/api/news?id=8ef4c847711b812db76cef7bb42143d35b90bf8308ea057dbb0a07d6878d43a6"
    }
  },
  {
    "ts": null,
    "headline": "23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer",
    "summary": "23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer",
    "url": "https://finnhub.io/api/news?id=213950876b4c499284383a138ce218d5152719290587d039417dd0800c19e6d9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749118636,
      "headline": "23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer",
      "id": 135055165,
      "image": "",
      "related": "REGN",
      "source": "DowJones",
      "summary": "23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer",
      "url": "https://finnhub.io/api/news?id=213950876b4c499284383a138ce218d5152719290587d039417dd0800c19e6d9"
    }
  },
  {
    "ts": null,
    "headline": "23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher",
    "summary": "23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process.",
    "url": "https://finnhub.io/api/news?id=a96271f0fd630dc4f26ed74e44f7f3ae1037d429110518be6ac3a49ed13fed5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749087660,
      "headline": "23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher",
      "id": 135037914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process.",
      "url": "https://finnhub.io/api/news?id=a96271f0fd630dc4f26ed74e44f7f3ae1037d429110518be6ac3a49ed13fed5d"
    }
  }
]